CIENCIASMEDICASNEWS

lunes, 22 de junio de 2026

Migration: a reality, not an emergency The Lancet ++...

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01240-7/fulltext?dgcid=raven_jbs_etoc_email Jun 20, 2026 Volume 407Number 10547p2473-2576 https://www.thelancet.com/journals/lancet/issue/vol407no10547/PIIS0140-6736(26)X2022-0

The Lancet Summit 2nd biennial cancer control in China Mar 18–21, 2027 | Shanghai, China

https://thelancetsummit.com/cancer-control-china/index.html The Lancet Summit 2nd biennial cancer control in China Mar 18–21, 2027 | Shanghai, China We are pleased to announce The Lancet Summit: 2nd biennial cancer control in China, a multi-track cancer control conference taking place in Shanghai, China, in 2027. The Lancet Summit: 2nd biennial cancer control in China will build on previous successful Summits and conferences on cancer control in Asia hosted by The Lancet, The Lancet Oncology, and other Lancet journals. This edition will be a collaboration between several Lancet journals (including The Lancet Haematology, The Lancet Obstetrics, Gynaecology & Women's Health, The Lancet Medical Imaging & Theranostics, and The Lancet) who have convened and collaborated with a renowned Advisory Board to produce a comprehensive programme and a stellar faculty of speakers. Over 3 days from Mar 19-21, 2027, our esteemed faculty will tackle the challenges posed by common cancers through the opportunities provided by new technologies, including imaging and AI, in China through a lens of cancer control. We have curated a contemporary programme consisting of three parallel tracks covering haematological cancers, women's cancers, and cancer imaging. The meeting will also feature cross-cutting plenary sessions, of interest to all attendees, and a unique half-day symposium dedicated to AI in cancer research. Finally, we will showcase some of the latest research from across China and beyond in dedicated oral abstract sessions and via poster presentations. Of interest to all in the field of oncology, including physicians, nurses, pathologists, radiologists, oncologists, surgeons, palliative care specialists, epidemiologists, public health practitioners, researchers, and policy makers, The Lancet Summit offers you a unique opportunity to connect with leading experts, engage with cutting-edge research, and help shape the future of cancer control. We look forward to seeing you in Shanghai in 2027!

Postpartum haemorrhage

https://www.thelancet.com/series-do/postpartum-haemorrhage?dgcid=raven_jbs_etoc_feature_lancetpph26 Postpartum haemorrhage (PPH) is the leading cause of maternal mortality worldwide, occurring in an estimated 27 million women globally every year and causing about 43 000 maternal deaths. Common causes of PPH are uterine atony, trauma, retained placenta, and coagulopathy, with risk heightened by factors including caesarean birth, anaemia, and inadequate antenatal care. As outlined in this three-paper Series, prevention centres on addressing modifiable risk factors for PPH, reducing unnecessary caesarean sections, and administration of uterotonic prophylaxis. Early diagnosis by objective quantification of blood loss and monitoring of vital signs is crucial. Swift treatment following a standardised bundle, and avoiding delays along the management pathway, saves lives.

Obstetrics, Gynaecology, & Women’s Health

https://www.thelancet.com/collections/obstetrics-gynaecology-womens-health?dgcid=hubspot_email_infocusalerts-obgyn_feature&parent=001603%3Fdgcid%3Dhubspot_email_infocusalerts-obgyn_feature&utm_campaign=infocusalerts-obgyn&utm_medium=email&_hsenc=p2ANqtz-_18WtAMSQyDTWWDR4DSO29-jQBVNlnaO5C1TY1rDAjJQQpG2ahKUn-1OEaE_wu0UJPlUW-x2MPi-eWbDKFktSRCnkV2w&_hsmi=424677531&utm_content=424646479&utm_source=hs_email

Primary cervical screening using a universal offer of human papillomavirus self-testing versus usual care in Aotearoa New Zealand: a cluster-randomised, non-inferiority trial

Primary cervical screening using a universal offer of human papillomavirus self-testing versus usual care in Aotearoa New Zealand: a cluster-randomised, non-inferiority trial Prof Bev Lawton, FRNZCGPa Send email to bev.lawton@vuw.ac.nz ∙ Melanie Gibson, PhDa ∙ Tania Slater, PhDa ∙ Varsha Parag, MScb ∙ Kendall Stevenson, PhDa ∙ Anna Adcock, PhDa ∙ et al. https://www.thelancet.com/journals/lanogw/article/PIIS3050-5038(25)00201-8/abstract?utm_campaign=infocusalerts-obgyn&utm_medium=email&dgcid=hubspot_email_infocusalerts-obgyn_feature&_hsenc=p2ANqtz-85mq8xhdJwrY5FbDFmr9dcMRA4Rcd3maHtcp6bj_SN1cL-viRQxC32UhMGSGjBY5Ly0agRyEjgTDlI6J5Qusgg_up_mw&_hsmi=424677531&utm_content=424646479&utm_source=hs_email

Transforming the Landscape of Gynaecological Cancer: Advances in Prevention, Precision Surgery, and Innovative Systemic Therapies

https://www.thelancet.com/series-do/gynaecological-cancers-advances?dgcid=hubspot_email_infocusalerts-obgyn_feature_eclinmgyno26&utm_campaign=infocusalerts-obgyn&utm_medium=email&_hsenc=p2ANqtz-9PIJ862JrivBrQlDUbwAbkm_hogZ3sDxaW2OyXOP7pVOHwcPNdkTgpJJtWkzFwdmv1KDjcL5PtjBJtnAB61s4MkQSvEg&_hsmi=424677531&utm_content=424646479&utm_source=hs_email A three-paper Series examines how new strategies and technologies are transforming gynaecological cancer care, with a focus on prevention, precision surgery, and innovative systemic therapies. Paper 1 explores global efforts toward cervical cancer elimination, including progress in HPV vaccination and screening, alternative vaccine strategies, and WHO screening guidelines. Authors also propose targeted actions to accelerate elimination through innovation and more equitable strategies. Paper 2 discusses how computer-assisted and image-guided technologies are redefining surgical lymph node staging in gynaecological cancers. Paper 3 reviews the rapidly evolving field of antibody-drug conjugates (ADCs) in gynaecological cancers. The authors summarise mechanisms of action and findings from clinical trials, and address safety considerations, predictive biomarkers, and future directions for integrating ADCs into personalized treatment strategies.